Market Data 
Markets
Replies to post #211842 on Avid Bioservices Inc (CDMO)
Kancera strengthens patent rights related to ROR antibody therapy
..
..
..
About ROR
ROR is a family of receptor tyrosine kinase receptors originally reported to be linked to fetus development and consists of two receptors, ROR1 and ROR2. Today it is also known that ROR receptors play a role also for cancer cells. It has been shown that inhibition of ROR causes certain cancer cells to eliminate themselves through apoptosis. Since ROR receptors are not present in healthy cells in adults, it is anticipated that a drug targeting ROR will selectively attack the tumor much more forcefully than healthy tissue.
Kancera’s co-founder Professor Håkan Mellstedt has shown that Kancera´s ROR inhibitors are capable of killing cancer cells originating from pancreas and as well as leukemic cells. Professor Mellstedt and other scientists have further shown that ROR is a potential therapeutic target also in prostate-, breast- and lung cancer.
..
..
http://www.kancera.com/en/Press/Press-releases/Press-release/?releaseid=680359
so the puzzle gets bigger but at least we have a tie from Hakan Mellstedt to Gerald McMahon CEO of Kolltan...
Cambridge Healthtech Institute’s Second Annual
Rational Combination Cancer Immunotherapy
Designing and Implementing Strategies for Increasing the Efficacy of Cancer Immunotherapy by Combining Checkpoint Inhibitors and Biotherapeutics
August 25-26
8:30 Immune Checkpoint Modulation: Rational Design of Combination Strategies
Michael A. Postow, M.D., Assistant Attending Physician, Melanoma and Immunotherapeutics Service, Memorial Sloan-Kettering Cancer Center
The immune system can be manipulated to enhance antitumor immunity. Efficacy has been demonstrated by approaches that block immune checkpoints, but not all patients benefit from treatment and improved outcomes are needed. Therapeutic approaches combining multiple immune checkpoint inhibitors with standard anticancer agents (radiotherapy, targeted therapy, and chemotherapy) are of great interest. Current approaches and a framework for the future will be discussed.
9:00 Expansion and Activation of T Cells via the Targeting of the Immunosuppressive Ligand Phosphatidylserine (PS): Combination Strategy with Conventional, Targeted, and Checkpoint Inhibitor Therapy
Jeff T. Hutchins, Ph.D., Vice President, Preclinical Research, Peregrine Pharmaceuticals
The underlying cause for the failure of current therapies is the persistent and multifocal immune suppression in the tumor microenvironment that drives the absence of pre-existing antitumor T cells. Bavituximab blocks PS-mediated immunosuppression (decreasing MDSCs) by reprograming immune cells in the tumor microenvironment to enhance anticancer activity. Pre-clinical, translational, and clinical results using bavituximab with conventional and immunotherapy combinations promotes a robust, anti-tumor T cell mediated response to enhance cancer therapy.
11:30 The TAM Receptor Tyrosine Kinase Family and Their Potential to Modulate Macrophage and Dendritic Cell Function Create Opportunities to Combine with T Cell Checkpoint Drugs
Jerry McMahonJerry McMahon, Ph.D., President & CEO, Kolltan Pharmaceuticals
TAM receptor tyrosine kinases and their cognate ligands play a key role in immune homeostasis through signaling in macrophage and dendritic cells and regulating the adaptive immune response. Modulation of the activation of these receptors may up- or down-regulate immune homeostasis for the treatment of cancer and other diseases. Inhibition of Axl and MerTK are under investigation to potentiate the effectiveness of biologic agents that interfere with T cell checkpoints in tumor immunology.
...
...
http://www.imvacs.com/Combination-Cancer-Immunotherapy/
Hakan Mellstedt : Peregrine Pharmaceuticals KOL
.... ok, so lately we've brought in some puzzle pieces for Greg Lemke <> Xetrios <> Salks Institute and a PS Targeting Patent and all other associated patents of Lemkes's and Salks all sold to "Kolltan"
so the puzzle gets bigger but at least we have a tie from Hakan Mellstedt to Gerald McMahon CEO of Kolltan...and PAV lists of some have shown Standish Fleming as well
...
...
..
Combination Immunotherapy Strategies
8:25 Chairperson’s Opening Remarks
Jeff T. Hutchins, Ph.D., Vice President, Preclinical Research, Peregrine Pharmaceuticals
Michael A. Postow
8:30 Immune Checkpoint Modulation: Rational Design of Combination Strategies
Michael A. Postow, M.D., Assistant Attending Physician, Melanoma and Immunotherapeutics Service, Memorial Sloan-Kettering Cancer Center
The immune system can be manipulated to enhance antitumor immunity. Efficacy has been demonstrated by approaches that block immune checkpoints, but not all patients benefit from treatment and improved outcomes are needed. Therapeutic approaches combining multiple immune checkpoint inhibitors with standard anticancer agents (radiotherapy, targeted therapy, and chemotherapy) are of great interest. Current approaches and a framework for the future will be discussed.
Jeff T. Hutchins
9:00 Expansion and Activation of T Cells via the Targeting of the Immunosuppressive Ligand Phosphatidylserine (PS): Combination Strategy with Conventional, Targeted, and Checkpoint Inhibitor Therapy
Jeff T. Hutchins, Ph.D., Vice President, Preclinical Research, Peregrine Pharmaceuticals
The underlying cause for the failure of current therapies is the persistent and multifocal immune suppression in the tumor microenvironment that drives the absence of pre-existing antitumor T cells. Bavituximab blocks PS-mediated immunosuppression (decreasing MDSCs) by reprograming immune cells in the tumor microenvironment to enhance anticancer activity. Pre-clinical, translational, and clinical results using bavituximab with conventional and immunotherapy combinations promotes a robust, anti-tumor T cell mediated response to enhance cancer therapy.
...
...
...
11:30 The TAM Receptor Tyrosine Kinase Family and Their Potential to Modulate Macrophage and Dendritic Cell Function Create Opportunities to Combine with T Cell Checkpoint Drugs
Jerry McMahon, Ph.D., President & CEO, Kolltan Pharmaceuticals
TAM receptor tyrosine kinases and their cognate ligands play a key role in immune homeostasis through signaling in macrophage and dendritic cells and regulating the adaptive immune response. Modulation of the activation of these receptors may up- or down-regulate immune homeostasis for the treatment of cancer and other diseases. Inhibition of Axl and MerTK are under investigation to potentiate the effectiveness of biologic agents that interfere with T cell checkpoints in tumor immunology.
12:00 pm Late-Breaking Presentation
...
..
http://www.imvacs.com/Combination-Cancer-Immunotherapy/
AI
